The Indiana Department of Health (IDOH) has asked ISMA to inform members about several therapeutics that are now available to prescribe for COVID-19 patients at high risk for progression to severe disease. In a Feb. 4 provider update, IDOH said it has worked to ensure that four medications are available across the state and will continue to add locations.

The four treatments available for prescription are:

• GSK’s sotrovimab monoclonal antibody infusion.
• Merck’s oral antiviral molnupiravir, which reports a 30% reduction in hospitalization.
• Pfizer’s oral antiviral paxlovid, which reports reducing the risk of hospitalization or death by 89%.
• Veklury (remdesivir) given as a 3-day outpatient infusion, which in a study resulted in an 87% lower risk of hospitalization or death than placebo.

IDOH referred physicians to the following essential resources:

• IDOH COVID Therapeutics Provider Update (Feb. 4, 2022)
• Map of COVID-19 Treatment Sites in Indiana
• NIH COVID Treatment Guidelines
• Side-by-Side Comparison of Outpatient COVID Therapies
• Therapeutics Outpatient Decision Tree
• Sample COVID-19 Therapeutics Referral Form
• IDOH Updates on Monoclonal Antibodies and Veklury (Remdesivir)